Article de Périodique
Amphetamine-group substances and HIV. HIV in people who use drugs 5 (2010)
Auteur(s) :
COLFAX G. ;
G. M. SANTOS ;
P. CHU ;
E. VITTINGHOFF ;
PLUDDEMANN A. ;
S. KUMAR ;
C. HART
Article en page(s) :
458-474 (Online 20 July)
Sous-type de document :
Revue de la littérature / Literature review
Refs biblio. :
143
Domaine :
Drogues illicites / Illicit drugs
Langue(s) :
Anglais
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Résumé :
Amphetamine-group substances are used worldwide and are more prevalent than either cocaine or opioids. We reviewed published reports about amphetamine-group substances and did a meta-analysis of randomised controlled trials of behavioural interventions for their use. Most research was done in developed countries. Many, but not all, studies show an association between amphetamine-group substance use and risk of HIV infection. Much use of amphetamine-group substances is non-injection and is associated with increased HIV risk, particularly in men who have sex with men. The structural, social, interpersonal, and personal factors that link to amphetamine-group substance use and HIV risk are poorly understood. 13 studies, with a cumulative sample size of 1997 individuals, qualified for the meta-analysis. Overall, high-intensity behavioural interventions were moderately effective in reducing use of amphetamine-group substances (effect size 0.28, 95% CI 0.13-0.44). We did not find conclusive evidence that behavioural interventions as a group are more effective than are passive or minium treatment for reduction of amphetamine-group substance use or sexual risk behaviours. The search for effective, scalable, and sustainable interventions for amphetamine-group substance use, including pharmacotherapies, should be supported and encouraged. [Author's abstract]
Affiliation :
HIV Prevention Section, San Francisco Department of Public Health, San Francisco, CA ; University of California, San Francisco, CA, United States / Etats-Unis